Evidence map›Paper›PMID 29976219›Full record

ArticleRetrovirology2018

Quantitation of the latent HIV-1 reservoir from the sequence diversity in viral outgrowth assays.

Art F Y Poon, Jessica L Prodger, Briana A Lynch, Jun Lai, Steven J Reynolds, Jingo Kasule, Adam A Capoferri, Susanna L Lamers, Christopher W Rodriguez, Daniel Bruno and 4 more

Abstract read
In one paragraph

Article in Retrovirology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Addressing an HIV cure in LMIC.Retrovirology · 2021
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Art F Y PoonDepartment of Pathology and Laboratory Medicine, Western University, London, ON, Canada. apoon42@uwo.ca.ORCID 0000-0003-3779-154X
Jessica L ProdgerDepartment of Microbiology and Immunology, Western University, London, ON, Canada.
Briana A LynchLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, USA.
Jun LaiDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Steven J ReynoldsDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Jingo KasuleRakai Health Sciences Program, Kalisizo, Uganda.
Adam A CapoferriDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Susanna L LamersBioInfoExperts, LLC, Thibodaux, LA, USA.
Christopher W RodriguezBioInfoExperts, LLC, Thibodaux, LA, USA.
Daniel BrunoGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Stephen F PorcellaGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Craig MartensGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Thomas C QuinnLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, USA.
Andrew D ReddLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, USA.

Funding

Infectious Diseases Research Technologies Core - RMLZICAI001052 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$133.3M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
CIHR 201302MFE-300992CIHR BOP-149562CIHR FRN-130609CIHR PJT-153391Gilead HIV Cure Grants Program 90072171Institute of Infection and Immunity PJT-155990Institute of Infection and Immunity PJT-156178Ontario Genomics Institute OGI-131
6 · The paper itself

Abstract

backgroundThe ability of HIV-1 to integrate into the genomes of quiescent host immune cells, establishing a long-lived latent viral reservoir (LVR), is the primary obstacle to curing these infections. Quantitative viral outgrowth assays (QVOAs) are the gold standard for estimating the size of the replication-competent HIV-1 LVR, measured by the number of infectious units per million (IUPM) cells. QVOAs are time-consuming because they rely on culturing replicate wells to amplify the production of virus antigen or nucleic acid to reproducibly detectable levels. Sequence analysis can reduce the required number of culture wells because the virus genetic diversity within the LVR provides an internal replication and dilution series. Here we develop a Bayesian method to jointly estimate the IUPM and variant frequencies (a measure of clonality) from the sequence diversity of QVOAs.

resultsUsing simulation experiments, we find our Bayesian approach confers significantly greater accuracy over current methods to estimate the IUPM, particularly for reduced numbers of QVOA replicates and/or increasing actual IUPM. Furthermore, we determine that the improvement in accuracy is greater with increasing genetic diversity in the sample population. We contrast results of these different methods applied to new HIV-1 sequence data derived from QVOAs from two individuals with suppressed viral loads from the Rakai Health Sciences Program in Uganda.

conclusionsUtilizing sequence variation has the additional benefit of providing information on the contribution of clonality of the LVR, where high clonality (the predominance of a single genetic variant) suggests a role for cell division in the long-term persistence of the reservoir. In addition, our Bayesian approach can be adapted to other limiting dilution assays where positive outcomes can be partitioned by their genetic heterogeneity, such as immune cell populations and other viruses.

Indexed as

Genetic VariationGenome, ViralViral LoadVirus LatencyBayes TheoremCD4-Positive T-LymphocytesComputer SimulationDisease ReservoirsHIV-1HIV InfectionsHumansVirus ActivationVirus ReplicationBayesian inferenceHIV-1Latent viral reservoirLimiting dilution assayNext-generation sequencingViral outgrowth assay

Identifiers

PMID29976219
PMCPMC6034329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.